Langenbeck's Archives of Surgery

, Volume 392, Issue 3, pp 353–358

Systemic immune dysfunction in pancreatic cancer patients

  • Bertram Poch
  • Errki Lotspeich
  • Marco Ramadani
  • Susanne Gansauge
  • Hans G. Beger
  • Frank Gansauge
Original Article

Abstract

Background and aims

We investigated the immune status in 32 pancreatic cancer patients (PC) in comparison with healthy controls (HC).

Materials and methods

Using flow cytometry, peripheral blood lymphocytes (PBL) were characterized by the expression of surface markers for T helper cells (CD4), T suppressor cells (CD8), B cells (CD19) and NK cells (CD56). The blastogenic response of PBL was analyzed after stimulation with concavalin A (ConA), phytohemagglutinin (PHA), pokeweed mitogen (PWM) and anti-CD3 antibodies. The serum levels of TNF-α, IL-1β, IL-2, IL-10, IL-12, IL-18, IL-1RA, sIL-2R and TGF-β were determined by ELISA.

Results

No differences in the distribution of peripheral immunocytes in PC were found, whereas the blastogenic response of peripheral blood lymphocytes (PBL) after stimulation with PHA or anti-CD3 antibodies was significantly decreased in PC. In PC, we found reduced serum levels of IL-2 and significantly elevated levels of TNF-α, TGF-β1, IL-10, IL-2R, IL-1β and IL-1RA.

Conclusion

These data provide evidence for a systemic immune dysfunction in pancreatic cancer patients characterized by a shift towards a T helper cell type 2 cytokine profile, a significant elevation of substances related to T cell suppression and a reduced blastogenic response to PHA and anti-CD3 antibodies of PBL.

Keywords

Pancreas Cancer Immune dysfunction Cytokines 

References

  1. 1.
    Warshaw AL, Fernandez-del Castillo C (1992) Pancreatic carcinoma. N Engl J Med 326:455–465PubMedCrossRefGoogle Scholar
  2. 2.
    Gansauge S, Gansauge F, Beger HG (1996) Molecular oncology in pancreatic cancer. J Mol Med 74:313–320PubMedCrossRefGoogle Scholar
  3. 3.
    Finke J, Ferrone S, Frey A, Mufson A, Ochoa A (1999) Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol Today 20:158–160PubMedCrossRefGoogle Scholar
  4. 4.
    Gastman BR, Johnson DE, Whiteside TL, Rabinowich H (1999) Caspase-mediated degradation of T-cell receptor zeta-chain. Cancer Res 59:1422–1427PubMedGoogle Scholar
  5. 5.
    Gansauge S, Gansauge F, Yang Y, Muller J, Seufferlein T, Ramadani M, Beger HG (1998) Interleukin 1beta-converting enzyme (caspase-1) is overexpressed in adenocarcinoma of the pancreas. Cancer Res 58:2703–2706PubMedGoogle Scholar
  6. 6.
    Birk D, Gansauge F, Gansauge S, Schwarz A, Beger HG (1999) Levels of serum neopterin are increased in pancreatic cancer patients and correlate with the prognosis. Eur J Med Res 4:156–160PubMedGoogle Scholar
  7. 7.
    Gansauge F, Gansauge S, Rau B, Scheiblich A, Poch B, Schoenberg MH, Beger HG (1997) Low serum levels of soluble CD44 variant 6 are significantly associated with poor prognosis in patients with pancreatic carcinoma. Cancer 80:1733–1739PubMedCrossRefGoogle Scholar
  8. 8.
    Manfras BJ, Reuter S, Wendland T, Kern P (2002) Free in PMC increased activation and oligoclonality of peripheral CD8(+) T cells in the chronic human helminth infection alveolar echinococcosis. Infect Immun 70:1168–1174PubMedCrossRefGoogle Scholar
  9. 9.
    Chouaib S, Asselin-Paturel C, Mami-Chouaib F, Caignard A, Blay JY (1997) The host–tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today 18:493–497PubMedCrossRefGoogle Scholar
  10. 10.
    Betsholtz C, Bergh J, Bywater M, Pettersson M, Johnsson A, Heldin CH, Ohlsson R, Knott TJ, Scott J, Bell GI et al (1987) Expression of multiple growth factors in a human lung cancer cell line. Int J Cancer 39:502–507PubMedCrossRefGoogle Scholar
  11. 11.
    Smith JJ, Derynck R, Korc M (1987) Production of transforming growth factor alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle. Proc Natl Acad Sci USA 84:7567–7570PubMedCrossRefGoogle Scholar
  12. 12.
    Bellone G, Smirne C, Mauri FA, Tonel E, Carbone A, Buffolino A, Dughera L, Robecci A, Pirisi M, Emanuelli G (2006) Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol Immunother 55:684–698PubMedCrossRefGoogle Scholar
  13. 13.
    Halak BK, Maguire HC Jr, Lattime EC (1999) Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res 59:911–917PubMedGoogle Scholar
  14. 14.
    Huang M, Wang J, Lee P, Sharma S, Mao JT, Meissner H, Uyemura K, Modlin R, Wollman J, Dubinett SM (1995) Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res 55:3847–3853PubMedGoogle Scholar
  15. 15.
    Pellegrini P, Berghella AM, Del Beato T, Cicia S, Adorno D, Casciani CU (1996) Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother 42:1–8PubMedCrossRefGoogle Scholar
  16. 16.
    Schmitz-Winnenthal FH, Volk C, Z’graggen K, Galindo L, Nummer D, Ziouta Y, Bucur M, Weitz J, Schirrmacher V, Buchler MW, Beckhove P (2005) High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. Cancer Res 65:10079–10087PubMedCrossRefGoogle Scholar
  17. 17.
    Asselin-Paturel C, Echchakir H, Carayol G, Gay F, Opolon P, Grunenwald D, Chouaib S, Mami-Chouaib F (1998) Quantitative analysis of Th1, Th2 and TGF-beta1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients. Int J Cancer 77:7–12PubMedCrossRefGoogle Scholar
  18. 18.
    Kurtzman SH, Anderson KH, Wang Y, Miller LJ, Renna M, Stankus M, Lindquist RR, Barrows G, Kreutzer DL (1999) Cytokines in human breast cancer: IL-1alpha and IL-1beta expression. Oncol Rep 6:65–70PubMedGoogle Scholar
  19. 19.
    Yanagimoto H, Takai S, Satoi S, Toyokawa H, Takahashi K, Terakawa N, Kwon AH, Kamiyama Y (2005) Impaired function of circulating dendritic cells in patients with pancreatic cancer. Clin Immunol 114:52–60PubMedCrossRefGoogle Scholar
  20. 20.
    Lygidakis NJ, Berberabe AE, Spentzouris N, Dedemadi G, Kalligas T, Loukas G, Sotiropoulou V (1998) A prospective randomized study using adjuvant locoregional chemo-immunotherapy in combination with surgery for pancreatic carcinoma. Hepatogastroenterology 45:2376–2381PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Bertram Poch
    • 1
  • Errki Lotspeich
    • 2
  • Marco Ramadani
    • 3
  • Susanne Gansauge
    • 3
  • Hans G. Beger
    • 1
  • Frank Gansauge
    • 1
  1. 1.Center for Oncological, Endocrinological and Minimal-access SurgeryNeu-UlmGermany
  2. 2.Department of SurgeryArmy HospitalUlmGermany
  3. 3.Pancreatic Cancer Research GroupUniversity of UlmUlmGermany

Personalised recommendations